Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Fibromun, Darleukin
Philogen S.p.A.
Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)
1 trial -
Fludarabine Teva 25 mg/ml solution à diluer pour injection ou perfusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, LN-145, Proleukin 18 x 106 IE Poeder voor oplossing voor injectie of infusie, Cyclophosphamide Injection 1 g., Fludarabine 50mg Powder For Solution For Injection Or Infusion, Endoxan, Флударабин Актавис 25 mg/ml концентрат за инжекционен или инфузионен разтвор, Fludarabinefosfaat – PCH 25 mg/ml, concentraat voor oplossing voor injectie/infusie, FLUDARAB
Iovance Biotherapeutics B.V.
Metastatic Non-Small-Cell Lung Cancer
1 trial -
Fluorouracil 50mg/ml Injection., FOLINIC ACID, Eftozanermin alfa, Telisotuzumab adizutecan, Oxaliplatin 5 mg/ml concentrate for solution for infusion
AbbVie Deutschland GmbH & Co. KG
Adenocarcinoma of the gastroesophageal junction
1 trial -
Fluorouracil Injection 25 mg/ml, solution for injection, Oncofolic 50 mg/ml, Injektions-/Infusionslösung, Irinotecan Hydrochloride 20 mg/mL concentrate for solution for infusion
Wuhan Createrna Science and Technology Co., Ltd
Metastatic Colorectal Cancer
1 trial -
G-Pen Mini™ (glucagon injection)
Xeris Biopharma Holdings
Hypoglycemia
1 trial -
G-Pen Mini™ (glucagon injection)
Xeris Biopharma Holdings
Diabetes Mellitus, Type 1
2 trials -
GEN3014 DP, DARZALEX 1800 mg solution for injection
Genmab A/S
Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse Large B Cell Lymphoma (DLBCL) Acute Myeloid Leukemia (AML)
1 trial -
GIA632, Placebo to GIA632 150 mg/mL solution for injection
Novartis Pharmaceuticals
Atopic dermatitis
1 trial -
GL0034 4 mg/ml, 1 ml per vial, GL0034 3 mg/ml, 1 ml per vial, Same solution as for GL0034 without drug substance; solution for subcutaneous injection; volume identical to dose of test product, GL0034 1mg/ml, 0.6ml per vial, GL0034 1 mg/ml, 1 ml per vial
Lacuna Pharma Pty Ltd
Type 2 diabetes mellitus
1 trial -
GRANISETRON EXTENDED RELEASE INJECTION (GERSC)
Heron Therapeutics
Chemotherapy-induced Nausea and Vomiting
1 trial -
GT719 Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hematological Malignancy (Leukemia- Lymphoma)
1 trial -
Galvokimig, Placebo matching Test 0.9% sodium chloride solution for injection
Lacuna Pharma Pty Ltd
Atopic Dermatitis
1 trial -
Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)
Astra Zeneca AB
Recipients of allogeneic stem cell transplantation
1 trial -
Glucagon RTU Injection With Insulin Pump Reduction
Xeris Biopharma Holdings
Hypoglycemia
1 trial -
Golimumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Placebo for Guselkumab, Golimumab and JNJ-78934804, JNJ-78934804
Janssen-Cilag International N.V.
Moderately to Severely Active Crohn's Disease
1 trial -
Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Placebo to Guselkumab and Golimumab and JNJ-78934804, Golimumab, JNJ-78934804
Janssen-Cilag International N.V.
Moderately to Severely Active Ulcerative Colitis
1 trial -
HEPCLUDEX 2 mg powder for solution for injection, VIR-2218, VIR-3434
Vir Biotechnology
Chronic Hepatitis D Virus (HDV) Infection
1 trial -
HS_SW01 cells injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ankylosing Spondylitis
1 trial -
HS_SW01 cells injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Primary Ovarian Insufficiency (Poi)
1 trial -
HYCAMTIN 4 mg powder for concentrate for solution for infusion, TAXOL 6 mg/ml, concentrato per soluzione per infusione., Neulasta 6 mg solution for injection, Caelyx pegylated liposomal 2 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion
SUTRO BIOPHARMA, INC.
Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)
1 trial -
HYDROCORTISONE, PREDNISOLONE ACETATE PH. EUR., ASCIMINIB HYDROCHLORIDE, CYTARABINE, DEXAMETHASONE, BLINATUMOMAB, Asciminib, METHOTREXATE, DBL methotrexate injection, VINCRISTINE SULFATE, DEXAMETHASONE SODIUM PHOSPHATE
Novartis Pharmaceuticals
relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)
1 trial -
HarMono-T 5 microlitres/mL gas and solvent for dispersion for injection/infusion
Lacuna Pharma Pty Ltd
Ultrasound contrast agent, for diagnostic purposes (to assess indeterminate kidney lesions)
1 trial -
Herceptin 150 mg powder for concentrate for solution for infusion, Enhertu 100 mg powder for concentrate for solution for infusion, Fluorouracil Injection, 50 mg/ml, solution for injection, Ziihera 300 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Xeloda 500 mg film-coated tablets, Xeloda 150 mg film-co
Boehringer Ingelheim
gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, esophageal adenocarcinoma
1 trial -
Hexyon suspension for injection in pre-filled syringe Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)., MenQuadfi solution for injection Meningococcal Group A, C, W and Y conjugate vaccine, RotaTeq oral solution Rotavirus vaccine (live), Bexsero suspension for injection in pre-filled syringe Meningococcal group B Vaccine (rDNA, component, adsorbed), MenPenta SD, Prevenar 13 suspension for in
Sanofi-aventis Healthcare Pty Ltd
Meningococcal immunization
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources